The first day of Enabling Technologies 2003 focused on the natural history of Alzheimer's disease, fundamental cell biology, and mechanisms of neurodegeneration.
Enabling Technologies 2002 Workshop Summary Pathways and Target Discovery: Bar Harbor 2002 Lead Discovery: Bar Harbor 2002 Mouse Models: Bar Harbor 2002 Infrastructure Development: Bar Harbor 2002 Enabling Technologies for Alzheimer Disease Research: 2002 ...
This report summarizes discussions at the second workshop on Enabling Technologies for Alzheimer's Disease (AD), held in August 2002 in Bar Harbor, Maine.
A majority of investigators agree that AβPP processing, Aβgeneration, Aβ degradation, and Aβaggregation play a major role in Alzheimer's disease.
Lead discovery is hampered by the absence of good cell-based assays in which to screen libraries against AβPP secretases and other targets.
A key controversy revolved around the value of available mouse models.
Future recommendations from the Enabling Technologies for Alzheimer's Disease Workshop in Bar Harbor, Maine.
Enabling Technologies 2001 Workshop Summary Summary of Scientific Discussions: Bar Harbor Summary of Technology Discussions: Bar Harbor Enabling Technologies for Alzheimer Disease Research: 2001 Bar Harbor Workshop ...
In August 2001, a diverse group of academic and industry investigators from within and outside of Alzheimer's disease research participated in this workshop in Bar Harbor, Maine.
Robert Balaban opened the discussion by observing that heart disease and AD research share certain characteristics, including a weak familial linkage, poor penetrance of some of the known risk factors, and a poor understanding of the interplay between environmental and behavioral factors with gene-gene interactions.
Tim Clark began by laying out recommendations about the information infrastructure required if many groups want to be able to do collective experimentation, to share data, and to exploit automated pattern recognition in that shared data.
Controlling diabetes and hypertension and stopping smoking can slash dementia risk.
Expansions in ataxin 2 predispose people to the ALS end of the ALS-FTD spectrum, and never cause pure FTD, according to a new French study.
As β-secretase inhibitors head into Alzheimer’s disease trials, researchers are paying close attention to what else BACE1 does besides snip amyloid-β from APP...
Today, the MetLife Foundation honored Yueming Li and Lennart Mucke with its 2013 Awards for Medical Research in Alzheimer’s Disease...
No filters selected